Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
(Date:6/30/2015)... , June 30, 2015  July 4 th ... of independence, and the spirit and people behind it. To ... has partnered with USA Medical Card, ... increase funding for programs that empower independence for our disabled ... and help more people afford their prescriptions. "Due ...
(Date:6/30/2015)... June 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... neuroblocking technology to treat obesity, metabolic diseases, and other ... public offering  of 40,229,886 units. Each unit consists of ... A warrant to purchase one share of common stock, ... one share of common stock, at a purchase price ...
Breaking Medicine Technology:Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... 3 Australian researchers have developed gene expression ... colorectal growths from non-cancerous controls. , , ... conference in Chicago, the preliminary findings are the ... Flinders University and Australian healthcare company, Clinical Genomics ...
... Day 3 And All Subsequent Study Visits - , ... Pharma Co., Ltd., (DSP) announced today that positive results from ... of patients with schizophrenia have been published in The ... placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a ...
Cached Medicine Technology:Advance in Bowel Cancer Test Research 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:7/1/2015)... (PRWEB) , ... July 01, ... ... in the communities of southeast Alabama, southwest Georgia and the Florida Panhandle, ... TelmedIQ as its primary secure text messaging and clinical communications workflow solution ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... the legal medical cannabis space, created a web-based resource where legal cannabis ... Harvest Financial brings together visionary entrepreneurs and medical marijuana advocates looking to strategically ...
(Date:7/1/2015)... ... ... Effective June 9, 2015, the Radiology Business Management Association (RBMA) ... process has been in place since the RBMA was founded in 1968 with all ... succeeds Keith E. Chew, MHA, CMPE, as president. Ms. Taylor has been an RBMA ...
(Date:6/30/2015)... , ... July 01, 2015 , ... Carey Danis ... lawsuits being managed in a West Virginia federal court. The court document outlined ... trial date for the 26 cases.¹ , Carey Danis & Lowe is a personal ...
(Date:6/30/2015)... ... ... Down is a reputable source of authentic Kid Rock tickets at the DTE Energy ... road again this summer in what is one of the most affordable summer tours in ... this year at the XFINITY Theatre in Hartford, CT on June 24th and the blockbuster ...
Breaking Medicine News(10 mins):Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 2Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 3Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 4Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2
... 2,000,000 Minnesotans have designated their wishes to donate,on their ... April 1, 2008 When,Minnesotans apply for or renew ... with the opportunity to check the,box designating themselves organ ... taken that important step and said yes to the,life-saving ...
... CA, April 1, 2008 Rap music has gone from ... substance abuse to one that often glorifies illegal drug use, ... genre covering nearly two decades. The study is published ... a peer reviewed scientific journal., Positive portrayals of drug use ...
... protein helps virus conceal itself from body,s defenses , , ... discovered how HIV -- the virus that causes AIDS -- ... body,s immune cells. , They explained that when a normal ... immune system responds and produces cells that quickly eliminate the ...
... With Melanin-Rich Skin Tones, SKILLMAN, N.J., April 1, 2008 ... skin tones between,the ages of 25 and 54 experience dry ... only skin concern for these women. Women with,richer skin tones ... due to the excess melanin in their skin that often ...
... NEW YORK, April 1 SpongeTech Delivery,Systems, Inc. ... Darryl,Strawberry Foundation are pleased to announce corporate involvement ... for the New,York Mets, I am excited about ... have been a great tool for children with,autism, ...
... April 1, 2008 Valensa International,introduced Crannose(TM) ... Natural Products Expo West Conference. This patent-pending,supplement, ... known benefits of cranberry with D-mannose, a ... Larch tree. The,product is available in bulk, ...
Cached Medicine News:Health News:Minnesotans Demonstrate Commitment to Organ and Tissue Donation 2Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 2Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 3Health News:Scientists Uncover How HIV Hides Inside Cells 2Health News:AMBI(R) Introduces SOFT & EVEN(TM) 2Health News:AMBI(R) Introduces SOFT & EVEN(TM) 3Health News:SpongeTech Delivery Systems, Inc. to Donate to The Darryl Strawberry Foundation!! 2Health News:Crannose(TM) Extra Strength Women's Health Formula Targets Urinary Tract Infections 2
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... wrap than VICRYL knitted mesh. Especially suitable ... contained. Predictable absorption. Polyglactin 910 has been ... ,VICRYL (polyglactin 910) woven mesh is prepared ... and lactide, derived respectively from glycolic and ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: